In April 2026, UK Biobank reported that de‑identified participant data had appeared for sale on an e‑commerce platform, followed by similar data uploaded to public code repositories. The platform was closed, suspending work by more than 22,000 researchers across 60 countries. For cardiovascular science, which has been transformed by UK Biobank through polygenic risk scores, cardiac magnetic resonance (CMR) phenotyping, and artificial intelligence (AI) electrocardiogram (ECG) models, these events are a global warning.
The author argues that “de‑identified” is not “anonymous”. Residual re‑identification risk is real, especially for carriers of rare cardiomyopathy variants or individuals at polygenic extremes. This is not a UK problem alone: global resources such as All of Us, China Kadoorie Biobank, and FinnGen face similar challenges. Failure to act may erode public trust and slow cross‑cohort validation of cardiovascular risk tools.
The author calls on cardiovascular journals to require trusted research environment (TRE) statements, biobank‑specific data availability language, safeguards for linked code repositories, and enhanced review for high‑risk studies. Institutions, funders, and researchers share complementary responsibilities. The core conclusion is clear: technical safeguards protect participant trust, but they cannot replace it. Cardiovascular science must earn the trust of the next generation of volunteers through accountable governance.
The work titled “Safeguarding the World’s Biobanks: A call to cardiovascular science”, was published on Cardiac Research (accepted on May. 9, 2026).
DOI: 10.1097/re9.0000000000000017
Regions: Asia, China, Europe, United Kingdom
Keywords: Science, Life Sciences